DBV Technologies | DBVT - Current Liabilities


DBV Technologies reported $54.3M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
DBV Technologies USD 54.3M 2.5M Jun/2026
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026